DE602006007323D1 - VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN - Google Patents

VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN

Info

Publication number
DE602006007323D1
DE602006007323D1 DE602006007323T DE602006007323T DE602006007323D1 DE 602006007323 D1 DE602006007323 D1 DE 602006007323D1 DE 602006007323 T DE602006007323 T DE 602006007323T DE 602006007323 T DE602006007323 T DE 602006007323T DE 602006007323 D1 DE602006007323 D1 DE 602006007323D1
Authority
DE
Germany
Prior art keywords
baff
treatment
suffering
induced
induced suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006007323T
Other languages
English (en)
Inventor
Charles Mackay
Fabienne Mackay
Susan Kalled
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Garvan Institute of Medical Research
Biogen Inc
Biogen MA Inc
Original Assignee
Garvan Institute of Medical Research
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garvan Institute of Medical Research, Biogen Idec Inc, Biogen Idec MA Inc filed Critical Garvan Institute of Medical Research
Publication of DE602006007323D1 publication Critical patent/DE602006007323D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
DE602006007323T 2005-01-28 2006-01-27 VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN Active DE602006007323D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64809805P 2005-01-28 2005-01-28
PCT/US2006/003127 WO2006081516A2 (en) 2005-01-28 2006-01-27 USE OF BAFF TO TREAT Th2-MEDIATED CONDITIONS

Publications (1)

Publication Number Publication Date
DE602006007323D1 true DE602006007323D1 (de) 2009-07-30

Family

ID=36741125

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006007323T Active DE602006007323D1 (de) 2005-01-28 2006-01-27 VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN

Country Status (9)

Country Link
US (1) US20080254030A1 (de)
EP (1) EP1855711B1 (de)
AU (1) AU2006209237B2 (de)
CA (1) CA2596276A1 (de)
DE (1) DE602006007323D1 (de)
DK (1) DK1855711T3 (de)
HK (1) HK1110803A1 (de)
NZ (1) NZ560285A (de)
WO (1) WO2006081516A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
PT2275449T (pt) 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US20030091565A1 (en) * 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
KR20140077946A (ko) * 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
WO2007123765A2 (en) * 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
EP2396035A4 (de) * 2009-02-12 2012-09-12 Human Genome Sciences Inc Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur förderung von transplantationstoleranz
US8735347B2 (en) 2011-02-02 2014-05-27 Children's Hospital Medical Center Regulation of energy metabolism and obesity by modulating B cell activating factor (BAFF, BLYS) or BAFF signaling

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6541224B2 (en) * 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6689579B1 (en) * 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US20030175208A1 (en) * 1996-10-25 2003-09-18 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US5969102A (en) * 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
US20030022239A1 (en) * 1997-06-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20010010925A1 (en) * 1997-11-17 2001-08-02 Steven R. Wiley Methods of detecting target nucleic acids of tnf-delta
US20020055624A1 (en) * 1997-11-17 2002-05-09 Steven R. Wiley Tnf-delta ligand and uses thereof
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US20030095967A1 (en) * 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
PL198934B1 (pl) * 1999-01-25 2008-08-29 Apoxis Sa Zastosowanie przeciwciała swoistego wobec rozpuszczalnego BAFF lub aktywnego fragmentu przeciwciała i zastosowanie rozpuszczalnego BAFF lub jego aktywnego fragmentu
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
US6475987B1 (en) * 1999-05-06 2002-11-05 National Jewish Medical And Research Center Tall-1 receptor homologues
DK1210425T4 (en) * 1999-08-17 2015-08-10 Apotech R & D Sa BAFF receptor (BCMA), an immunoregulatory agent
UA74798C2 (uk) * 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2399387C (en) * 2000-02-11 2015-11-03 Biogen, Inc. Heterologous polypeptide of the tnf family
US20040013674A1 (en) * 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
PT2275449T (pt) * 2000-06-16 2016-12-27 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
US6475686B2 (en) * 2000-07-28 2002-11-05 Canon Kabushiki Kaisha Fixing method
US20030091565A1 (en) * 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
ES2309224T3 (es) * 2001-12-21 2008-12-16 Immunex Corporation Polipeptidos recombinantes.
US20030211509A1 (en) * 2002-03-26 2003-11-13 Wiley Steven R. TNF-delta ligand and uses thereof

Also Published As

Publication number Publication date
US20080254030A1 (en) 2008-10-16
NZ560285A (en) 2011-04-29
AU2006209237A1 (en) 2006-08-03
CA2596276A1 (en) 2006-08-03
EP1855711B1 (de) 2009-06-17
WO2006081516A3 (en) 2007-05-03
DK1855711T3 (da) 2009-10-12
AU2006209237B2 (en) 2010-06-24
HK1110803A1 (en) 2008-07-25
EP1855711A2 (de) 2007-11-21
WO2006081516A2 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE503752T1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE502007006880D1 (de) Verwendung von gallium (iii) komplexen zur behandlung von melanomen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition